[1]CurrentPatentAssignee:UNIVERSITYOFDUNDEE;UNIVERSITYOFSTANDREWS-WO2008/29096,2008,A2Locationinpatent:Page/Pagecolumn23-24;36-37
[1]CurrentPatentAssignee:UNIVERSITYOFDUNDEE;UNIVERSITYOFSTANDREWS-WO2008/29096,2008,A2Locationinpatent:Page/Pagecolumn23-24;36-37
Title: An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.
Journal: Cell cycle (Georgetown, Tex.) 20120501
Title: Identification and characterization of novel sirtuin inhibitor scaffolds.
Journal: Bioorganic & medicinal chemistry 20091001
Title: Lain S, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13(5):454-63.
Title: Ladds MJGW, et al. Exploitation of DHODH and p53 activation as therapeutic targets - a case study in polypharmacology [published online ahead of print, 2020 Sep 8 J Biol Chem. 2020;jbc.RA119.012056.
Title: Dai W, et al. Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. Sci Rep. 2016 Mar 4;6:22622.
Title: Yuan H, et al. Tenovin-6 impairs autophagy by inhibiting autophagic flux. Cell Death Dis. 2017 Feb 9;8(2):e2608.
Title: Yuan H, et al. Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy. Oncotarget. 2017 Feb 28;8(9):14912-14924.
